The Indian Serology Institute said this year it plans to produce up to 60 million doses of a possible vaccine against the emerging coronavirus, which is undergoing clinical trials in Britain.
The Indian Sera Institute is the world’s largest vaccine maker by volume and is a candidate to mass produce the vaccine the Oxford University is developing, which began its experiment with humans last week, and is one of the pioneers in the global race to create a vaccine against the emerging corona virus.
About 3.05 million people were infected worldwide, and another 211,376 died from Covid-19, a respiratory disease caused by the Coronavirus.
Adar Punwala, CEO of the Serology Institute, said that although the effectiveness of the Oxford vaccine against Covid-19 had not yet been established, the Indian Sera Company decided to start manufacturing it after it proved successful in animal experiments and began experimenting in humans.
The Oxford vaccine is called (CHADOX1N Covid-19).
Bunwala added that he hoped for the success of the Oxford vaccine trials, which are due to end around September. Oxford scientists said last week that the main focus of initial trials is to confirm not only whether the vaccine is working, but whether it stimulates good immune responses and has no unacceptable side effects.